Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

R. Nussbaum | D. Steinemann | V. Pankratz | F. Couch | L. Andrews | B. Bonanni | O. Olopade | T. Rebbeck | B. Karlan | J. Benítez | Sofia Khan | R. Eeles | A. Spurdle | M. Southey | D. Easton | G. Rennert | M. Greene | K. Offit | A. Antoniou | Å. Borg | N. Loman | S. Buys | R. Berger | D. Eccles | D. Evans | G. Chenevix-Trench | H. Nevanlinna | U. Hamann | C. Lázaro | K. Nathanson | J. Cunningham | J. Garber | C. Isaacs | J. Dennis | M. Schmidt | Andrew Lee | H. Meijers-Heijboer | A. Meindl | R. Schmutzler | Xianshu Wang | I. Andrulis | G. Glendon | A. Mulligan | P. Radice | P. Peterlongo | S. Manoukian | A. Jakubowska | J. Lubiński | K. Durda | S. Slager | A. Toland | F. Fostira | J. Simard | S. Neuhausen | C. Sutter | S. Wang-gohrke | A. V. D. van den Ouweland | J. Vijai | M. Robson | L. McGuffog | A. Godwin | E. Friedman | N. Tung | C. V. van Deurzen | E. Imyanitov | A. Osorio | N. Ditsch | B. Wappenschmidt | N. Sevenet | S. Domchek | D. Stoppa-Lyonnet | N. Lindor | M. Porteous | G. Giannini | D. Frost | O. Sinilnikova | S. Mazoyer | F. Hogervorst | C. Engel | C. Singer | C. Szabo | K. Claes | J. Rantala | R. Platte | B. Arun | U. Jensen | S. Hart | F. Damiola | A. Arason | O. Díez | S. Hodgson | L. Faivre | G. Scuvera | L. Side | F. Nielsen | B. Buecher | A. Gerdes | P. James | B. Arver | M. Daly | R. B. van der Luijt | D. Goldgar | K. Kuchenbaecker | M. Thomassen | B. Ejlertsen | J. Lester | C. Cybulski | M. Teixeira | A. Brady | M. Rogers | A. Bojesen | J. Weitzel | M. Tischkowitz | L. Varesco | K. Kast | K. Rhiem | M. Terry | P. Mariani | B. Peissel | A. H. van der Hout | P. Morrison | C. Phelan | J. Gronwald | C. Aalfs | L. Izatt | C. Maugard | E. Oláh | C. Brewer | R. Davidson | C. Olswold | P. Soucy | D. Barrowdale | S. Healey | M. Piedmonte | I. Blanco | M. Montagna | T. Caldés | E. J. van Rensburg | S. Ramus | M. Caligo | R. Janavicius | J. Wijnen | S. Ellis | J. Adlard | J. Cook | F. Douglas | A. Donaldson | E. Rouleau | F. Prieur | L. Papi | M. Tibiletti | S. Volorio | N. Arnold | A. Gehrig | D. Niederacher | H. Plendl | R. Varon‐Mateeva | G. Rodriguez | A. Fink-Retter | C. Rappaport | G. Pfeiler | M. Tea | Y. Laitman | I. Pedersen | L. Steele | Á. Teulé | P. Mai | S. Agata | M. de la Hoya | M. Durán | C. M. Dorfling | L. Tihomirova | J. Barwell | I. Cass | Hebon | V. Bonadona | M. Longy | K. Ong | L. Walker | A. Mensenkamp | I. Konstantopoulou | Anne Lincoln | V. Caux‐Moncoutier | A. Berger | L. Barjhoux | R. Dolcetti | C. Lefol | M. Menéndez | H. Ehrencrona | M. J. Kennedy | Daphne Geschwantler Kaulich | J. Hays | G. Roversi | Gemo Study Collaborators | T. Van Maerken | M. Corines | Claire Foo | A. Lee | Lauren M. Jacobs | B. Markiefka | Emily J. Hallberg | E. Hallberg | I. Tafur | Nadja Bogdanova-Markov | Kep van Roozendaal | Katarzyna Jaworska–Bieniek | kConFab investigators | Breast Cancer Family Registry | Thomas v O Hansen | M. Hander | JL de Lange | A. Teule | J. Cook | Wang Shan | Embrace Study | M. Kennedy | Radka Platte | Steve Ellis | D. Evans | J. de Lange | W. Shan | E. Friedman | D. Evans | M. Teixeira | Curtis L. Olswold | Johanna Rantala | D. Evans

[1]  Yurii B. Shvetsov,et al.  Identification of six new susceptibility loci for invasive epithelial ovarian cancer , 2015, Nature Genetics.

[2]  Kconfab Investigators,et al.  Identification of six new susceptibility loci for invasive epithelial ovarian cancer , 2015 .

[3]  Wei Lu,et al.  Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. , 2013, American journal of human genetics.

[4]  Wei Lu,et al.  Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer , 2013, Nature Genetics.

[5]  Patrick Neven,et al.  Genome-wide association studies identify four ER negative–specific breast cancer risk loci , 2013, Nature Genetics.

[6]  Jaana M. Hartikainen,et al.  Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.

[7]  W. Chung,et al.  Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk , 2013, PLoS genetics.

[8]  D. Altshuler,et al.  Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk , 2013, PLoS genetics.

[9]  B. Carter.  Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2013 .

[10]  Jane E. Carpenter,et al.  A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. , 2012, Human molecular genetics.

[11]  D. Easton,et al.  Evaluation of Association Methods for Analysing Modifiers of Disease Risk in Carriers of High‐Risk Mutations , 2012, Genetic epidemiology.

[12]  Daniel J. Park,et al.  19p13.1 is a triple-negative-specific breast cancer susceptibility locus. , 2012, Cancer research.

[13]  W. Chung,et al.  Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[14]  Mads Thomassen,et al.  Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers , 2012, Breast Cancer Research.

[15]  Päivi Heikkilä,et al.  Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[16]  Mads Thomassen,et al.  Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 , 2011, Breast Cancer Research.

[17]  A. Sigurdsson,et al.  Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer , 2008, Nature Genetics.

[18]  F. Couch,et al.  RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. , 2007, American journal of human genetics.

[19]  Georgia Chenevix-Trench,et al.  An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) , 2007, Breast Cancer Research.

[20]  A. Whittemore,et al.  BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays , 2007, The American journal of surgical pathology.

[21]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[22]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[24]  H. Frierson,et al.  Medullary carcinoma of the breast: interobserver variability in histopathologic diagnosis. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[25]  A. Gentile,et al.  Medullary carcinoma of the breast. A multicenter study of its diagnostic consistency. , 1993, Archives of pathology & laboratory medicine.

[26]  K. Lange,et al.  Programs for pedigree analysis: Mendel, Fisher, and dGene , 1988, Genetic epidemiology.

[27]  J. Fleiss,et al.  Intraclass correlations: uses in assessing rater reliability. , 1979, Psychological bulletin.

[28]  H. Bush,et al.  Breast Cancer Research , 1978, British Journal of Cancer.